In addition, we classified NB patients from the whole dataset into a high-expression group (ALKBH5-high or FTO-high) and a low-expression group (ALKBH5-low or FTO-low) based on the median expression of ALKBH5 or FTO. This evidence concerns the gene ALKBH5 and neuroblastoma.